Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.

Paxlovid (nirmatrelvir/ritonavir) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/41717886

Akhil Deepak Vatvani; Arif Nur Muhammad Ansori; Cucunawangsih Cucunawangsih; Timotius Ivan Hariyanto

Feb 20, 2026